Elan

113 results

The Sharp Building at Hogan Place, Dublin 2

Perrigo, the leading global healthcare supplier, is to rent an impressive new €20 million headquarters office building developed by the McGarrell Rei(...)

Aisling Quirke in Johannesburg: an active member of Business Ireland Southern Africa

Aisling Quirke was bitten by the travel bug after spending time in Konstanz, Germany, on a government scholarship while still at secondary school. Sh(...)

Tony O’Brien, director-general of the HSE, arriving  for a meeting of the Joint Committee on Health, on issues  surrounding the CervicalCheck Programme, at Leinster House on Wednesday. Photograph: Dara Mac Dónaill

Taoiseach Leo Varadkar has defended his relationship with the chairman of the Mater Hospital, who chairs the board of a US firm that HSE director-gene(...)

Alkermes reckons more than eight million people in the US alone suffer from a major depressive disorder. File photograph: Getty Images

Shares in Irish biopharma group Alkermes jumped sharply after the United States Food and Drug Administration (FDA) agreed to reconsider a depression d(...)

Kelly Martin has taken over as interim chief executive of US group Novan. He will juggle his time with his existing role as CEO of Malin Corporation. Photograph: Joe St Leger

Kelly Martin, the chief executive of Dublin-headquartered life sciences group Malin Corporation, has been appointed as interim chief executive of derm(...)

Richard Pops, Alkermes chief executive, received a lower salary last year. Photograph: Dara Mac Dónaill / The Irish Times

Executives at Irish-headquartered biopharma group Alkermes received lower overall remuneration last year. The group, which is domiciled in Ireland fo(...)

The falure of its Alzheimer medicine - known as Solanezumab, or Sola -  wiped $10 billion off Lilly’s market capitalisation in a single day.

The suspense inside the offices of Eli Lilly this autumn was all but unbearable. After working on a drug to fight Alzheimer’s disease for 15 years, em(...)

Tysabri, the multiple sclerosis drug developed by Elan, may be sold again as Perrigo examines options.

Consumer health and generics group Perrigo is reviewing strategic options for royalty rights from sales of its multiple sclerosis drug Tysabri after r(...)

Paul Galvin: “I can’t be bothered trawling through websites when you can just go into a store and buy there and then.”

Are you a saver or a spender? I enjoy both equally, but fortunately over the years I’ve managed to be a better saver than a spender – just about! Do(...)

Under the terms of the transaction, Malin has invested $20 million in Poseida with a commitment to invest a further $10 million next year subject to the achievement of certain milestones

Malin, the Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, is to take a 31 per cent (...)

  • « First
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
  • Last »